NASDAQ:CLDX Celldex Therapeutics (CLDX) Stock Price, News & Analysis → This AI Trade Machine Made 1,729%* (With 89% Wins) (From Prosper Trading Academy) (Ad) Free cldx Stock Alerts $36.30 +0.04 (+0.11%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$35.65▼$36.7450-Day Range$36.26▼$51.8852-Week Range$22.11▼$53.18Volume324,978 shsAverage Volume611,116 shsMarket Capitalization$2.03 billionP/E RatioN/ADividend YieldN/APrice Target$66.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Celldex Therapeutics alerts: Email Address Celldex Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside81.8% Upside$66.00 Price TargetShort InterestBearish12.08% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.85) to ($3.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.72 out of 5 starsMedical Sector862nd out of 914 stocksDiagnostic Substances Industry11th out of 12 stocks 3.4 Analyst's Opinion Consensus RatingCelldex Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCelldex Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.08% of the outstanding shares of Celldex Therapeutics have been sold short.Short Interest Ratio / Days to CoverCelldex Therapeutics has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Celldex Therapeutics has recently increased by 2.90%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCelldex Therapeutics does not currently pay a dividend.Dividend GrowthCelldex Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLDX. Previous Next 2.1 News and Social Media Coverage News SentimentCelldex Therapeutics has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.Search InterestOnly 14 people have searched for CLDX on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Celldex Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Celldex Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.70% of the stock of Celldex Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Celldex Therapeutics are expected to decrease in the coming year, from ($2.85) to ($3.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celldex Therapeutics is -12.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celldex Therapeutics is -12.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelldex Therapeutics has a P/B Ratio of 4.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Celldex Therapeutics Stock (NASDAQ:CLDX)Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Read More CLDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLDX Stock News HeadlinesApril 19, 2024 | investing.comCelldex completes patient enrollment for Phase 2 urticaria trialApril 19, 2024 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Celldex Therapeutics (NASDAQ:CLDX)April 28, 2024 | Tranzact (Ad)What is Medicare Supplement Insurance?Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. April 17, 2024 | msn.comCelldex Hails Enrolment News, Shares Poke AheadApril 17, 2024 | finance.yahoo.comCelldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible UrticariaApril 17, 2024 | globenewswire.comCelldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible UrticariaApril 11, 2024 | seekingalpha.comCLDX Celldex Therapeutics, Inc.March 17, 2024 | finance.yahoo.comCLDX Aug 2024 70.000 callApril 28, 2024 | Tranzact (Ad)What is Medicare Supplement Insurance?Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. March 16, 2024 | finance.yahoo.comCLDX Aug 2024 50.000 callMarch 16, 2024 | finance.yahoo.comCLDX Apr 2024 65.000 callMarch 16, 2024 | finance.yahoo.comCLDX Apr 2024 40.000 callMarch 16, 2024 | finance.yahoo.comCLDX Jan 2025 15.000 putMarch 8, 2024 | globenewswire.comCelldex Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceMarch 6, 2024 | ca.finance.yahoo.comCLDX Jan 2025 30.000 putMarch 6, 2024 | ca.finance.yahoo.comCLDX Jan 2025 70.000 callMarch 6, 2024 | finance.yahoo.comCelldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care ConferenceMarch 5, 2024 | finance.yahoo.comCelldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesMarch 5, 2024 | globenewswire.comCelldex Therapeutics to Present at TD Cowen's 44th Annual Health Care ConferenceMarch 5, 2024 | globenewswire.comCelldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesMarch 2, 2024 | investing.comCelldex announces $400.4 million public stock offeringMarch 1, 2024 | markets.businessinsider.comCelldex Therapeutics Prices Public Offering Of 8.52 Mln Shares At $47.00/shrFebruary 29, 2024 | globenewswire.comCelldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common StockFebruary 29, 2024 | finance.yahoo.comWall Street Analysts Predict a 26.53% Upside in Celldex (CLDX): Here's What You Should KnowFebruary 28, 2024 | globenewswire.comCelldex Therapeutics Announces Proposed Public Offering of Common StockFebruary 27, 2024 | ca.finance.yahoo.comCLDX Mar 2024 50.000 putFebruary 27, 2024 | finance.yahoo.comCelldex Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsSee More Headlines Receive CLDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2024Today4/27/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryBiotechnology Current SymbolNASDAQ:CLDX CUSIP15117B10 CIK744218 Webwww.celldex.com Phone(908) 454-7120Fax908-454-1911Employees160Year Founded1983Price Target and Rating Average Stock Price Target$66.00 High Stock Price Target$90.00 Low Stock Price Target$27.00 Potential Upside/Downside+81.8%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-141,430,000.00 Net Margins-2,054.46% Pretax Margin-2,054.76% Return on Equity-41.06% Return on Assets-37.65% Debt Debt-to-Equity RatioN/A Current Ratio13.87 Quick Ratio13.87 Sales & Book Value Annual Sales$6.88 million Price / Sales294.94 Cash FlowN/A Price / Cash FlowN/A Book Value$9.08 per share Price / Book4.00Miscellaneous Outstanding Shares55,900,000Free Float53,833,000Market Cap$2.03 billion OptionableOptionable Beta1.49 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Anthony S. Marucci M.B.A. (Age 62)Founder, President, CEO & Director Comp: $1.14MDr. Tibor Keler (Age 65)Founder, Chief Scientific Officer & Executive VP Comp: $739.03kMr. Sam Martin (Age 53)Senior VP, CFO, Secretary & Treasurer Comp: $617.26kDr. Margo Heath-Chiozzi M.D. (Age 67)Senior Vice President of Regulatory Affairs Comp: $614.12kDr. Diane C. Young M.D. (Age 67)Senior VP & Chief Medical Officer Comp: $643.5kProf. Joseph P. Schlessinger Ph.D. (Age 79)Co-Founder & Member of Scientific Advisory Board Ms. Sarah Cavanaugh (Age 49)Senior Vice President of Corporate Affairs & Administration Patrick TillSenior Director of Investor Relations & Corporate CommunicationsMr. Freddy A. Jimenez Esq. (Age 55)Senior VP & General Counsel Comp: $579.7kDr. Ronald A. Pepin (Age 68)Chief Business Officer & Senior VP Comp: $441.84kMore ExecutivesKey CompetitorsMyriad GeneticsNASDAQ:MYGNIntellia TherapeuticsNASDAQ:NTLAQuidelOrthoNASDAQ:QDELNeogenNASDAQ:NEOGMeridian BioscienceNASDAQ:VIVOView All CompetitorsInstitutional OwnershipAssenagon Asset Management S.A.Bought 90,931 shares on 4/24/2024Ownership: 0.163%Mirador Capital Partners LPSold 3,151 shares on 4/18/2024Ownership: 0.187%Overbrook Management CorpSold 555 shares on 4/16/2024Ownership: 0.013%Los Angeles Capital Management LLCBought 6,733 shares on 4/5/2024Ownership: 0.012%Vanguard Group Inc.Bought 427,827 shares on 3/11/2024Ownership: 5.450%View All Institutional Transactions CLDX Stock Analysis - Frequently Asked Questions Should I buy or sell Celldex Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CLDX shares. View CLDX analyst ratings or view top-rated stocks. What is Celldex Therapeutics' stock price target for 2024? 5 brokers have issued 12 month price targets for Celldex Therapeutics' stock. Their CLDX share price targets range from $27.00 to $90.00. On average, they anticipate the company's share price to reach $66.00 in the next year. This suggests a possible upside of 81.8% from the stock's current price. View analysts price targets for CLDX or view top-rated stocks among Wall Street analysts. How have CLDX shares performed in 2024? Celldex Therapeutics' stock was trading at $39.66 on January 1st, 2024. Since then, CLDX stock has decreased by 8.5% and is now trading at $36.30. View the best growth stocks for 2024 here. Are investors shorting Celldex Therapeutics? Celldex Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 6,560,000 shares, an increase of 11.2% from the March 15th total of 5,900,000 shares. Based on an average trading volume of 952,500 shares, the days-to-cover ratio is presently 6.9 days. View Celldex Therapeutics' Short Interest. When is Celldex Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CLDX earnings forecast. How were Celldex Therapeutics' earnings last quarter? Celldex Therapeutics, Inc. (NASDAQ:CLDX) released its quarterly earnings results on Monday, February, 26th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.19. The biopharmaceutical company earned $4.13 million during the quarter, compared to analysts' expectations of $1.20 million. Celldex Therapeutics had a negative net margin of 2,054.46% and a negative trailing twelve-month return on equity of 41.06%. What ETFs hold Celldex Therapeutics' stock? ETFs with the largest weight of Celldex Therapeutics (NASDAQ:CLDX) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Tema Oncology ETF (CANC), ALPS Medical Breakthroughs ETF (SBIO) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Principal Healthcare Innovators ETF (BTEC). When did Celldex Therapeutics' stock split? Shares of Celldex Therapeutics reverse split on the morning of Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Celldex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and SCYNEXIS (SCYX). Who are Celldex Therapeutics' major shareholders? Celldex Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Mirador Capital Partners LP (0.19%), Assenagon Asset Management S.A. (0.16%), Overbrook Management Corp (0.01%) and Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Diane C Young, Elizabeth Crowley, Freddy A Jimenez, Samuel Bates Martin and Sarah Cavanaugh. View institutional ownership trends. How do I buy shares of Celldex Therapeutics? Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CLDX) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersMan Who Predicted 2008: “This Will be Worse.”AltimetryMysterious Gold Leverage Just AnnouncedStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
